Orhan SEZEN, Halil KAVGACI, Fazıl AYDIN, Evren FİDAN, Feyyaz ÖZDEMİR, Büent YILDIZ

Clinicopathological characteristics of triple-negative breast cancers in the northeast region of Turkey

Background: Triple-negative (TN) breast cancer is a subtype of breast cancer characterised by a loss of estrogen receptor (ER), progesterone receptor (PR) expression, and the absence of human epidermal growth factor (HER2) overexpression. Aims: To identify the relationships between clinicopathological characteristics of TN breast cancers in the northeast region of Turkey and disease free survival (DFS) and overall survival (OS). Study Design: Retrospective clinical study. Methods: Seven hundred and eighty non-metastatic breast cancer patients were enrolled in this study. The relationships between TN breast cancer and other breast cancers with respect to clinicopathological characteristics, as well as DFS and OS, were studied. Results: The triple-negative phenotype was detected in 204 patients (27.1%). Patients with triple-negative breast cancer had more grade 2-3 tumours compared to those with other types of breast cancer (92.5% versus 84.3%, p=0.004). Invasive ductal carcinoma histology, on the other hand, was less prevalent in patients with TN breast cancer (77% versus 84.5%, p=0.016). No significant differences were identified between the groups in other clinicopathological variables. Relapse and mortality rates were higher in the TN group during the follow-up of both groups [57 (27.9%) versus 89 (16.2%), p

PDF

___

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Cancer statistics. CA Cancer J Clin 2011;61:69-90. [CrossRef]
2. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747- 52. [CrossRef]
3. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005;116:340-50. [CrossRef]
4. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-23. [CrossRef]
5. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74. [CrossRef]
6. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007;109:25-32. [CrossRef]
7. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry. Cancer 2007;109:1721-8. [CrossRef]
8. Aksoy S, Dizdar O, Harputluoglu H, Altundag K. Demographic, clinical, and pathological characteristics of Turkish triple-negative breast cancer patients: single center experience. Ann Oncol 2007;18:1904-6. [CrossRef]
9. Suresh P, Batra U, Doval DC. Epidemiological and clinical profile of triple negative breast cancer at a cancer hospital in North India. Indian J Med Paediatr Oncol 2013;34:89-95. [CrossRef]
10. Li CY, Zhang S, Zhang XB, Wang P, Hou GF, Zhang J. Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study. Asian Pac J Cancer Prev 2013;14:3779-84. [CrossRef]
11. Mersin H, Yildirim E, Berberoglu U, Gülben K. The prognostic importance of triple negative breast carcinoma. Breast 2008;17:341-6. [CrossRef]
12. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 2009;113:357-70. [CrossRef]
13. Greene FL. AJCC cancer staging manual. 6th ed. New York: Springer; 2002. [CrossRef]
14. Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 1988;6:1076-87.
15. Kowalski PJ, Rubin MA, Kleer CG. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 2003;5:217-22. [CrossRef]
16. Arun B, Kilic G, Yen C, Foster B, Yardley D, Gaynor R, et al. Correlation Bcl-2 and p53 Expression in Primary Breast Tumors and Corresponding Metastatic Lymph Nodes. Cancer 2003;98;2554-9. [CrossRef]
17. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34. [CrossRef]
18. Kim JE, Ahn HJ, Ahn JH, Yoon DH, Kim SB, Jung KH, et al. Impact of triple-negative breast cancer phenotype on prognosis in patients with stage I breast cancer. J Breast Cancer 2012;15:197-202. [CrossRef]
19. Rhee J, Han SW, Oh DY, Kim JH, Im SA, Han W, et al. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer 2008;8:307. [CrossRef]
20. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triplenegative breast cancer. J Clin Oncol 2008;26:1275-81. [CrossRef]
21. Nishimura R, Arima N. Is triple negative a prognostic factor in breast cancer? Breast Cancer 2008;15:303-8. [CrossRef]
22. Yin WJ, Lu JS, Di GH, Lin YP, Zhou LH, Liu GY, et al. Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat 2008;115:325-33. [CrossRef]
23. Zhang HM, Xuan LX, Gao JD, Zhang BN, Zhao P. Clinical characteristics comparison between triple-negative and non-triple-negative breast cancer. Zhonghua Wai Ke Za Zhi 2009;47:506-10.
24. He Q, Wang J, Shao YG, Zhou XY, Shao ZM. Clinical-pathological characteristics and survival of triple negative breast cancer. Zhonghua Yi Xue Za Zhi 2009;89:243-7